药品首席执行官们敦促欧盟提高药品价格,以便在贸易紧张的情况下刺激卫生投资。 Drug CEOs urge EU to raise medicine prices to boost health investments amid trade tensions.

来自AstraZeneca、GlaxoSmithKline和Bayer等主要制药公司的首席执行官正在推动欧盟允许提高药品价格和增加医疗支出。 CEOs from major drug firms like AstraZeneca, GlaxoSmithKline, and Bayer are pushing the EU to allow higher medicine prices and increased health spending. 他们认为,如果没有更有力的奖励措施,欧洲在吸引研发和制造业投资方面将落后于美国,冒着保护公众健康的能力的风险。 They argue that without stronger incentives, Europe will lag behind the US in attracting R&D and manufacturing investments, risking its ability to protect public health. 执行官们警告说,目前的贸易紧张可能进一步侵蚀对欧盟的投资。 The executives warn that ongoing trade tensions could further erode investments in the EU.